µÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

    ¼ò ¤™
    • ¼ò
    • ·±
    • EN
    ¤œ
    Ïà¹ØÁ´½Ó
    • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    ÐÂÎÅ·¢²¼
    Press Release
    Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
    µÏÍþÖƵÏÍþ¹ú¼Ê | ºããå?5ÄêÑ­Ö¤¼¯ÝÍ 14²¿Ö¸ÄϹ²Ê¶¹²¼ö
    ·¢²¼ÈÕÆÚ£º2026/02/02
    ×ÖºÅ

    - ÂýÐÔÒÒÐ͸ÎÑ×£¨CHB£©µÄÖÎÁÆÊÇÒ»³¡³Ö¾ÃÕ½£¬»¼ÕßÐèÒª¸ßЧ¡¢°²È«µÄµÏÍþ¹ú¼ÊÎïÀ´³¤ÆÚ¿ØÖƲ¡¶¾¡¢ÑÓ»º¼²²¡½øÕ¹¡£

    - µ±Ç°Íƽø¡¶Öйú·ÀÖβ¡¶¾ÐÔ¸ÎÑ×Ðж¯¼Æ»®£¨2025¡ª2030Ä꣩¡·½ø³ÌÖУ¬¹æ·¶»¯µÄ¿¹²¡¶¾ÖÎÁÆ£¬ÊÇ´Ó¡°ÓÐЧ¿ØÖÆ¡±Ïò¡°¹¦ÄÜÐÔÖÎÓú¡±Âõ½øµÄ¿Æѧ»ù´¡ÓëºËÐÄ»·½Ú¡£

    - ´Ó48ÖÜ¡¢96ÖÜ¡¢144ÖÜÖ±ÖÁ240ÖÜ£¨5Ä꣩£¬ºããå?µÄ¿¹²¡¶¾ÁÆЧ¼°°²È«ÐÔÀú¾­Á˲»Í¬½×¶ÎÁÙ´²Ñо¿µÄ³¤ÆÚÑϸñÑéÖ¤¡£


    µÏÍþÖƵÏÍþ¹ú¼Ê×ÔÖ÷Ñз¢µÄÖйúÊ׸öÔ­Ñпڷþ¿¹ÒҸβ¡¶¾µÏÍþ¹ú¼ÊÎïºããå?£¨°¬Ã×Ìæŵ¸£Î¤£¬TMF£©£¬×Ô2021ÄêÉÏÊк󣬴ӹؼüµÄ¢óÆÚ×¢²áÑо¿µ½³¤´ï5ÄêµÄÕæʵÊÀ½ç³¤ÆÚËæ·Ã£¬»ýÀÛÁ˼áʵÇÒÍêÕûµÄÑ­Ö¤Ö¤¾ÝÌåϵ£¬Õ¹ÏÖ³ö³ÖÐøµÄ²¡¶¾ÒÖÖÆÄÜÁ¦¡¢ÓÅÒìµÄѪÇåѧת»»Ç±Á¦ÒÔ¼°×¿Ô½µÄ¹ÇÉö°²È«ÐÔ¡£ºããå? ÏȺó»ñµÃ¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2022Äê°æ£©¡·[1]¡¢¡¶¸ÎË¥½ßÕïÖÎÖ¸ÄÏ£¨2024Äê°æ£©¡·[2]¡¢¡¶Ô­·¢ÐԸΰ©ÕïÁÆÖ¸ÄÏ£¨2024Äê°æ£©¡·[3]ÒÔ¼°¡¶Öйú¸ßΣÈËȺÒÒÐ͸ÎÑײ¡¶¾ÔÙ¼¤»î·ÀÖÎÖ¸ÄÏ£¨2026Äê°æ£©¡·[4]µÈ14¸ö¹úÄÚȨÍþÖ¸ÄϹ²Ê¶ÍƼö£¬ÎªCHBµÄ³¤ÆÚ¹ÜÀíÌṩÁ˸üÓÅÑ¡Ôñ¡£


    01
    ¿ìËÙ¸ßЧ£¬³ÖÐøÒÖÖÆ

    • ¸øµÏÍþ¹ú¼Ê4Öܲ¡¶¾ÔØÁ¿Ã÷ÏÔϽµ£º¢óÆÚ48ÖÜÑо¿Êý¾ÝÏÔʾ£¬ÎÞÂÛÊÇHBeAgÑôÐÔ»¹ÊÇHBeAgÒõÐÔ»¼Õߣ¬TMF×éÔÚ¸øµÏÍþ¹ú¼ÊµÚ4ÖÜʱ²¡¶¾ÔØÁ¿¾ùÃ÷ÏÔϽµ£¬Ï½µ·ù¶È·Ö±ðΪ2.84ºÍ2.81 log10 IU/ml[5]¡£

    • 5Ä겡¶¾Ñ§ÒÖÖÆÂʸߴï95%£º¢óÆÚÍ·¶ÔÍ·Ñо¿ÖУ¬ºããå?ÖÎÁÆ48ÖܺÍ96ÖÜÔÚ²¡¶¾Ñ§Ó¦´ð£¨HBV DNA <20 IU/mL£©ÉϾù·ÇÁÓЧÓÚTDF¶ÔÕÕ×é[5,6]¡£ÇÒÁÆЧËæʱ¼ä³ÖÐøÌáÉý£ºÖÎÁÆ144ÖÜʱ£¬Î¬³ÖTMFÖÎÁÆ×黼ÕßHBV DNA <20 IU/mL±ÈÀý´ï86.2%[7]£»¶ø240ÖÜ£¨Ô¼5Ä꣩ʱ£¬ÕâÒ»±ÈÀý½øÒ»²½ÌáÉýÖÁ95%£¬ÆäÖиߴï92%µÄ»¼ÕßʵÏÖÁËHBV DNA<10 IU/mLµÄ¸ü¸ßÖÎÁƱê×¼[8]¡£Òâζ×ÅTMF³¤ÆÚÖÎÁÆÄÜʹ¾ø´ó¶àÊý»¼ÕßʵÏÖ²¡¶¾Ñ§ÒÖÖÆ¡£

    • ¸ß²¡¶¾ÔØÁ¿ÈËȺҲÃ÷ÏÔ»ñÒ棺¼´Ê¹ÔÚ»ùÏ߸߲¡¶¾ÔØÁ¿ÕâÒ»ÄÑÖÎÈËȺÖУ¬ºããå?ͬÑùÕ¹ÏÖ³öǿЧµÄ²¡¶¾Ñ§ÒÖÖÆÄÜÁ¦¡£ÔÚÍê³É144ÖÜÖÎÁÆʱ£¬Î¬³ÖTMFÖÎÁÆ×éÓëTDFתTMFÖÎÁÆ×éÖлùÏßHBV DNA¡Ý8 log10 IU/mlµÄ¸ß²¡¶¾ÔØÁ¿ÈËȺ·Ö±ðÓÐ78.1%ºÍ73.8%´ïµ½HBV DNA<20 IU/ml£¨P=0.402£©£¬ÓëÕûÌåÈËȺ½Ó½ü[7]¡£

    • 5ÄêHBeAgתÒõÂÊ68%£ºÑªÇåѧת»»£¨HBeAgתÒõ/ѪÇåѧת»»£©ÊÇCHBÖÎÁƵÄÖØҪĿ±ê£¬ÊÇ×·ÇóÁÙ´²ÖÎÓú¹ý³ÌÖеÄÖØÒª½×¶Î¡£»ùÏßHBeAgÑôÐÔÊÜÊÔÕßÖУ¨ÎÞÂÛ¿¹-HBeÑôÐÔ»òÒõÐÔ£©£¬µÚ144ÖÜʱά³ÖTMFÖÎÁÆ×éÓÐ37.0%³öÏÖHBeAgתÒõ[7]£»5Äêʱ£¬ÕâÒ»±ÈÀýÉý¸ßÖÁ68%[8]£¬¸ßÓÚÆäËûͬÀàµÏÍþ¹ú¼ÊÎïµÄ±¨¸æÊý¾Ý£¬Îª¸ü¶à»¼ÕßʵÏÖ¡°ÁÙ´²ÖÎÓú¡±´øÀ´ÁËÏ£Íû¡£

    • ALT¸´³£ÂʸüÓÅ£ºµÚ96ÖÜʱ£¬TMFÖÎÁÆ×éµÄALT¸´³£ÂʱÈTDF¶ÔÕÕ×éÏÔÖøÌá¸ßÔ¼10%£¨74.4% vs 64.9%£¬P=0.002£©[6]¡£

    02
    ³¤ÆÚʹÓ㬹ÇÉö°²È«

    ³¤ÆÚÓõÏÍþ¹ú¼ÊµÄ°²È«ÐÔÊÇCHBÖÎÁƵĺËÐĹØÇС£ºããå?ͨ¹ý´´ÐµÄÇ°ÌåµÏÍþ¹ú¼ÊÎïÉè¼Æ£¬ÔÚ±£³ÖǿЧÒÖÖƲ¡¶¾µÄͬʱ£¬ÏÔÖøÌáÉýÁ˳¤ÆÚÓõÏÍþ¹ú¼ÊµÄ°²È«ÐÔ¡£

    • ³¬80%»¼Õß¹ÇÃܶÈδϽµ£ºÓëTDFÏà±È£¬ºããå?¶Ô¹ÇÃܶȣ¨BMD£©µÄÓ°ÏìÏÔÖø¼õС¡£¢óÆÚ48ÖÜÊý¾ÝÏÔʾ£¬Æä÷Ų¿ºÍ¼¹ÖùBMDϽµ·ù¶ÈÏÔÖøСÓÚTDF£¨P<0.001£©[5]¡£ÕâÒ»ÓÅÊÆÔÚ³¤ÆÚÖÎÁÆÖеÃÒÔά³Ö£º5ÄêÑо¿Êý¾ÝÏÔʾ£¬×ÜÌåÉÏÓÐ80.5%µÄ»¼ÕßBMD ZÆÀ·ÖÎȶ¨»òÓÐÔö¼Ó¡£¼´Ê¹ÊÇÓÉTDFת»»ÖÁTMFÖÎÁƵĻ¼Õߣ¬Æä¹ÇÃܶÈÔÚת»»ºóÒ²µÃµ½Á˸ÄÉÆ[9]¡£

    • eGFRϽµÀÛ»ý·¢ÉúÂʼ«µÍ£ºÔÚÉö¹¦ÄÜÓ°Ïì·½Ã棬ºããå?ͬÑùÕ¹ÏÖ³ö¸ü¼ÑµÄ°²È«ÐÔÌØÕ÷¡£48ÖܺÍ96ÖÜÊý¾Ý¾ùÏÔʾ£¬Æä¹ÀËãÉöСÇòÂ˹ýÂÊ£¨eGFR£©Ï½µ·ù¶ÈÏÔÖøСÓÚTDF£¨P¾ù<0.05£©[5,6]¡£5Ä곤ÆÚËæ·ÃÖУ¬eGFR<60 mL/min/1.73 m?µÄÀÛ»ý·¢ÉúÂʼ«µÍ£¨¡Ü0.5%£©£¬Òâζ×ÅTMFÖÎÁÆÖоø´ó¶àÊý»¼ÕßµÄÉö¹¦ÄÜά³ÖÎȶ¨[8]¡£

    • ¶ÔѪ֬/ÌåÖØÎÞÃ÷ÏÔÓ°Ï죺ÓëTDF²»Í¬£¬ºããå?¶ÔѪ֬Æ׺ÍÌåÖصÄÓ°Ïì×ÜÌå³ÊÖÐÐÔÇÒÎȶ¨¡£5ÄêÆڼ䣬ÎÞÂÛά³ÖTMFÖÎÁÆ×黹ÊÇTDFתTMFÖÎÁÆ×飬»¼ÕßµÄѪָ֬±êºÍÌåÖؾù±£³ÖÎȶ¨[8]¡£

    03
    ת»»ÓõÏÍþ¹ú¼Ê£¬ÁÆЧ/°²È«ÐÔË«ÌáÉý

    Ñо¿»¹Ì½Ë÷ÁËTDF¾­Öλ¼Õßת»»ÖÁºããå?ÖÎÁƵĻñÒ棬ΪÁÙ´²ÖÎÁÆ·½°¸ÓÅ»¯ÌṩÁËÒÀ¾Ý¡£

    • ÁÆЧÌáÉý£º¢óÆÚ144ÖÜÊý¾ÝÏÔʾ£¬TDFÖÎÁÆ96Öܺóת»»ÖÁºããå?¼ÌÐøÖÎÁÆ48ÖÜ£¬»¼ÕßALT¸´³£ÂʽøÒ»²½ÏÔÖøÌáÉý11.4%£¨P<0.001£©£¬ÇÒ¸ÎÏËά»¯Ö¸±ê£¨FIB-4£©»ñµÃÏÔÖø¸ÄÉÆ£¨P=0.005£©£¬Í¬Ê±Î¬³ÖÁËÔ­ÓеIJ¡¶¾Ñ§Ó¦´ð[7]¡£5ÄêÊý¾ÝÏÔʾ£¬TDFתTMFÖÎÁÆ×黼ÕßͬÑùʵÏÖÁ˸ߴï94%µÄHBV DNA <20 IU/mL±ÈÀýºÍ63%µÄHBeAgתÒõÂÊ[8]¡£

    • ¹Ç/Éö°²È«ÐÔ¸ÄÉÆ£º°²È«ÐÔ·½Ã棬¢óÆÚ144ÖÜÊý¾ÝÏÔʾ£¬ÔÚ½ÓÊÜת»»ÖÎÁƺó£¬TDFתTMF×éµÄÉöСÇòÂ˹ýÂʺͼ¡ôûÇå³ýÂʽϵÚ96ÖÜ£¨TDFÖÎÁÆ£©·Ö±ðÉý¸ß£¨2.31¡À8.33£©ml/minºÍ£¨4.24¡À13.94£©ml/min£»TDFתTMF×éµÄ÷Ų¿ºÍ¼¹ÖùBMD·Ö±ð½ÏµÚ96ÖÜ£¨TDFÖÎÁÆ£©Éý¸ß0.75%ºÍ1.41%£¬±íÃ÷TDFת»»ÎªTMFÖÎÁƺó»¼ÕßµÄÉö¹¦Äܺ͹Ç÷À°²È«ÐԵõ½Á˸ÄÉÆ[10]¡£



    ×÷ΪÒҸο¹²¡¶¾ÖÎÁƵÄÒ»ÏßÓÅÑ¡µÏÍþ¹ú¼ÊÎºããå?ΪCHB»¼ÕßÌṩÁÆЧÓ밲ȫÐÔ²¢ÖصÄÖÎÁÆÑ¡Ôñ£¬²¢Õ¹ÏÖÁËÖйúÔ­ÑеÏÍþ¹ú¼ÊÎïÔÚÓ¦¶ÔÖØ´óÁÙ´²ÌôÕ½ÖеĴ´ÐÂÍ»ÆÆÓëʹÃüµ£µ±£¬ÎªÍƶ¯ÊµÏÖ¡°½¡¿µÖйú2030¡±Ïû³ý²¡¶¾ÐÔ¸ÎÑ×Σº¦µÄÕ½ÂÔÄ¿±ê¹±Ï׹ؼüÁ¦Á¿¡£

    ²Î¿¼ÎÄÏ×£º

    1.ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á,ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á. ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2022Äê°æ£©[J]. Öлª¸ÎÔಡÔÓÖ¾,2022,30(12):1309-1331. 

    2.ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á¸ÎË¥½ßÓëÈ˹¤¸Îѧ×é,ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÖØÐ͸β¡ÓëÈ˹¤¸Îѧ×é. ¸ÎË¥½ßÕïÖÎÖ¸ÄÏ£¨2024Äê°æ£©[J]. Öлª¸ÎÔಡÔÓÖ¾,2025,33(1):18-33.

    3.ÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»áÒ½Õþ˾. Ô­·¢ÐԸΰ©ÕïÁÆÖ¸ÄÏ(2024Äê°æ)[J]. ЭºÍҽѧÔÓÖ¾,2024,15(3):532-558. 

    4.¹ú¼Ò´«È¾²¡Ò½Ñ§ÖÐÐÄ,ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á,¡¶Öлª´«È¾²¡ÔÓÖ¾¡·±à¼­Î¯Ô±»á. Öйú¸ßΣÈËȺÒÒÐ͸ÎÑײ¡¶¾ÔÙ¼¤»î·ÀÖÎÖ¸ÄÏ£¨2026Äê°æ£©[J]. Öлª´«È¾²¡ÔÓÖ¾,2025, ÍøÂçÔ¤·¢±í.DOI:10.3760/cma.j.cn311365-20251118-00397

    5.Liu Z, Jin Q, Zhang Y, et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149.

    6.Liu Z, Jin Q, Zhang Y, et al. 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients. J Clin Transl Hepatol. 2023 Jun 28;11(3):649-660.

    7.ÁõÖÇãü,½ðÇåÁú,ÕÅÔ¾ÐÂ,µÈ. ÑÓ³¤»òת»»Îª°¬Ã×Ìæŵ¸£Î¤ÖÎÁÆÔÚÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÖеÄÁÆЧÆÀ¹À£ºÒ»Ïî¢óÆÚËæ»ú¶ÔÕÕÑо¿[J]. Öлª¸ÎÔಡÔÓÖ¾,2024,32(10):883-892. 

    8.Zhihong Liu. 5-Year Efficacy and Safety of Tenofovir Amibufenamide(TMF) in Chronic Hepatitis B Patients with Positive or Negative HBeAg: A Multicenter, Open-label, Phase IV study. APASL 2025.OP0155 

    9.Zhihong Liu,et al. Influencing Factors of Bone Mineral Density Decline in Chronic Hepatitis B Patients Treated With Tenofovir Amibufenamide Over 5 Years. AASLD 2025. Abstract No.1249

    10.ÁõÖÇãü,½ðÇåÁú,ÕÅÔ¾ÐÂ,µÈ. ÑÓ³¤»òת»»ÖÁ°¬Ã×Ìæŵ¸£Î¤ÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×»¼ÕߵݲȫÐÔ£ºÒ»Ïî¢óÆÚ¡¢¶àÖÐÐÄ¡¢Ëæ»ú¶ÔÕÕÑо¿[J]. Öлª¸ÎÔಡÔÓÖ¾,2024,32(10):893-903. 


    ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

    µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²7¿î£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

    ÃâÔðÉùÃ÷

    ±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

    Ç°Õ°ÐÔ˵Ã÷

    ±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

    2. ¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿